ReviewJournal of the National Cancer Institute2012
Second malignant neoplasms and cardiovascular disease following radiotherapy.
Review in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 224 citations in OpenAlex.
- Adherence to multiple health behaviours in cancer survivors: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2019Pooled it
- Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis.Cancer medicine · 2018Pooled it
- Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Pooled it
- Accelerated Premalignant Polyposis and Second Colon Cancers: Incriminating Immunosuppression, Radiotherapy, and Systemic Chemotherapy Agents.Journal of gastrointestinal cancer · 2016Pooled it
- Trial
- From Leukemia to Solid Tumors, Successful Multidisciplinary Management of Three Distinct Primary Cancers in a Single Patient: A Case Report.Clinical case reports · 2026Article
- Is Radiotherapy a Risk Factor for Melanoma?Dermatopathology (Basel, Switzerland) · 2025Review
- Review
- Comparison of lifetime attributable risk of post-irradiation secondary cancer of boron neutron capture therapy, proton beam therapy, and X-ray therapy for pediatric and adolescent and young adult patients.Clinical and translational radiation oncology · 2025Article
- The combined application of electromagnetic navigation and porcine fibrin sealant in microwave ablation of lung tumors.Heliyon · 2024Article
- Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysis.Basic and clinical andrology · 2024Article
- Impact of radiotherapy on second primary lung cancer incidence and survival in esophageal cancer survivors.Scientific reports · 2024Article
- Photosynthetic bacteria-based whole-cell inorganic-biohybrid system for multimodal enhanced tumor radiotherapy.Journal of nanobiotechnology · 2024Article
- Single-cell transcriptomic landscape reveals distinct tumourigenesis and immune microenvironments in secondary radiation-exposed rectal cancer.Clinical and translational medicine · 2024Article
- Article
- Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer.Cancers · 2023Article
- Cancer Treatment Using Different Shapes of Gold-Based Nanomaterials in Combination with Conventional Physical Techniques.Pharmaceutics · 2023Review
- Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques.Breast cancer (Dove Medical Press) · 2023Article
- Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study.Molecular medicine (Cambridge, Mass.) · 2022Article
- A Review of Web-Based Nutrition Information in Spanish for Cancer Patients and Survivors.Nutrients · 2022Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are among the most serious and life-threatening late adverse effects experienced by the growing number of cancer survivors worldwide and are due in part to radiotherapy. The National Council on Radiation Protection and Measurements (NCRP) convened an expert scientific committee to critically and comprehensively review associations between radiotherapy and SMNs and CVD, taking into account radiobiology; genomics; treatment (ie, radiotherapy with or without chemotherapy and other therapies); type of radiation; and quantitative considerations (ie, dose-response relationships). Major conclusions of the NCRP include: 1) the relevance of older technologies for current risk assessment when organ-specific absorbed dose and the appropriate relative biological effectiveness are taken into account and 2) the identification of critical research needs with regard to newer radiation modalities, dose-response relationships, and genetic susceptibility. Recommendation for research priorities and infrastructural requirements include 1) long-term large-scale follow-up of extant cancer survivors and prospectively treated patients to characterize risks of SMNs and CVD in terms of radiation dose and type; 2) biological sample collection to integrate epidemiological studies with molecular and genetic evaluations; 3) investigation of interactions between radiotherapy and other potential confounding factors, such as age, sex, race, tobacco and alcohol use, dietary intake, energy balance, and other cofactors, as well as genetic susceptibility; 4) focusing on adolescent and young adult cancer survivors, given the sparse research in this population; and 5) construction of comprehensive risk prediction models for SMNs and CVD to permit the development of follow-up guidelines and prevention and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.